Injective Labs, in partnership with 21Shares, has announced the launch of AINJ — Injective Staking Exchange-Traded Product (ETP) affiliated with INJ, including staking.
This fund will allow users to access INJ tokens through major traditional financial exchanges and brokerage firms, while also collecting rewards from staking.
The ETP will be traded on Euronext Amsterdam (AINJ NA) and Euronext Paris (AINJ FP). The product will be supported by 25 different banks and brokers, including Interactive Brokers, Saxo Bank, Swissquote and eToro, among others.
Theo Injective Labs:
“AINJ is not just a new financial product; it is a strategic move to bridge the gap between traditional finance (TradFi) and decentralized markets. As a regulated financial product, AINJ paves the way for broader institutional participation and adoption of INJ.”
This fund represents a major milestone in Injective's efforts to integrate with traditional financial institutions and markets.
INJ is trading at $25.88 at press time, down 1% over the past 24 hours, based on Coingecko data.
What is AINJ?
INJ is one of the few crypto tokens globally to have an associated ETP, underscoring the importance and innovation behind this product. ETPs, like AINJ, offer a simple way to participate in a diversified portfolio, combining the ease of stock trading with the benefits of mutual funds.
AINJ has $128.6 million in assets under management (AUM) and will charge a 2.5% fee. The product is designed to track Injective's performance and collect staking profits to reinvest in the ETP.
The token currently offers an estimated 19.38% staking reward, although this may change depending on network and market conditions.
The ETP will be secured by INJ, kept in cold storage by a custodian. Securities listed on the Euronext market are regulated under the single Euronext Rule Book, which harmonizes all applicable regulations where it operates.
21Shares is known for partnering with major crypto projects and has played a key role in promoting a Bitcoin spot ETF alongside Ark Invest. With over $3 billion in assets under management for their crypto products, the firm is well positioned to support the launch and success of AINJ.
Cryptocurrency ETP
Injective has now joined a select group of cryptocurrencies available to investors through traditional financial products. With a market capitalization of $2.4 billion, Injective is positioned to benefit from participation from institutional and individual investors.
The launch comes amid growing interest in ETPs linked to digital assets beyond Bitcoin as the market prepares for spot Ethereum ETFs to begin trading. Several companies have begun applying for licenses for Solana-linked ETPs.
Meanwhile, some industry experts believe that spot Ethereum ETFs have opened the floodgates for funds linked to other digital assets. However, others argue that the lack of an established futures market for these tokens could hinder the approval process for these products.
Source: https://tapchibitcoin.io/injective-labs-va-21shares-ra-mat-etp-lien-ket-voi-token-inj.html
